1
|
Villegas-Esguevillas M, Cho S, Vera-Zambrano A, Kwon JW, Barreira B, Telli G, Navarro-Dorado J, Morales-Cano D, de Olaiz B, Moreno L, Greenwood I, Pérez-Vizcaíno F, Kim SJ, Climent B, Cogolludo A. The novel K V7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit. Biomed Pharmacother 2023; 164:114952. [PMID: 37295249 DOI: 10.1016/j.biopha.2023.114952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 05/23/2023] [Accepted: 05/27/2023] [Indexed: 06/12/2023] Open
Abstract
KV7 channels exert a pivotal role regulating vascular tone in several vascular beds. In this context, KV7 channel agonists represent an attractive strategy for the treatment of pulmonary arterial hypertension (PAH). Therefore, in this study, we have explored the pulmonary vascular effects of the novel KV7 channel agonist URO-K10. Consequently, the vasodilator and electrophysiological effects of URO-K10 were tested in rat and human pulmonary arteries (PA) and PA smooth muscle cells (PASMC) using myography and patch-clamp techniques. Protein expression was also determined by Western blot. Morpholino-induced knockdown of KCNE4 was assessed in isolated PA. PASMC proliferation was measured by BrdU incorporation assay. In summary, our data show that URO-K10 is a more effective relaxant of PA than the classical KV7 activators retigabine and flupirtine. URO-K10 enhanced KV currents in PASMC and its electrophysiological and relaxant effects were inhibited by the KV7 channel blocker XE991. The effects of URO-K10 were confirmed in human PA. URO-K10 also exhibited antiproliferative effects in human PASMC. Unlike retigabine and flupirtine, URO-K10-induced pulmonary vasodilation was not affected by morpholino-induced knockdown of the KCNE4 regulatory subunit. Noteworthy, the pulmonary vasodilator efficacy of this compound was considerably increased under conditions mimicking the ionic remodelling (as an in vitro model of PAH) and in PA from monocrotaline-induced pulmonary hypertensive rats. Taking all together, URO-K10 behaves as a KCNE4-independent KV7 channel activator with much increased pulmonary vascular effects compared to classical KV7 channel activators. Our study identifies a promising new drug in the context of PAH.
Collapse
Affiliation(s)
- Marta Villegas-Esguevillas
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| | - Suhan Cho
- Department of Physiology, College of Medicine, Seoul National University, Seoul, South Korea
| | - Alba Vera-Zambrano
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| | - Jae Won Kwon
- Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain
| | - Bianca Barreira
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| | - Göcken Telli
- Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
| | - Jorge Navarro-Dorado
- Departamento de Fisiología, Facultad de Farmacia, Universidad Complutense, Madrid, Spain
| | - Daniel Morales-Cano
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| | - Beatriz de Olaiz
- Department of Thoracic Surgery, Hospital Universitario de Getafe, Getafe, Spain
| | - Laura Moreno
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| | - Iain Greenwood
- Vascular Biology Research Centre, Institute of Molecular and Clinical Sciences, St George's University of London, United Kingdom
| | - Francisco Pérez-Vizcaíno
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| | - Sung Joon Kim
- Department of Physiology, College of Medicine, Seoul National University, Seoul, South Korea
| | - Belén Climent
- Departamento de Fisiología, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.
| | - Angel Cogolludo
- Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
| |
Collapse
|
2
|
Chow JW, Yan MM, Zhao H, Li ZR, Zhang Q, Zhong MK, Qiu XY. Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database. Expert Opin Drug Saf 2022:1-9. [DOI: 10.1080/14740338.2023.2145280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Jun-Wei Chow
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
- School of Pharmacy, Fudan University, Shanghai, China
| | - Ming-Ming Yan
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
| | - Hui Zhao
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
| | - Zi-Ran Li
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
| | - Qian Zhang
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
| | - Ming-Kang Zhong
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
| | - Xiao-Yan Qiu
- Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
3
|
Antigny F. Role of Ion Channels in the Development of Pulmonary Arterial Hypertension. Biomolecules 2022; 12:biom12101373. [PMID: 36291582 PMCID: PMC9599897 DOI: 10.3390/biom12101373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2022] [Accepted: 09/22/2022] [Indexed: 11/16/2022] Open
Affiliation(s)
- Fabrice Antigny
- INSERM UMR_S 999 «Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique», Hôpital Marie Lannelongue, 133, Avenue de la Résistance, F-92350 Le Plessis Robinson, France
| |
Collapse
|